Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases-Reference-Cited by-同舟云学术

Combined use of nivolumab and ipilimumab in Japanese patients with melanoma: a multicentre retrospective study of 111 cases

Published:2023-04-05 Issue:2 Volume:189 Page:223-250
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Fujisawa Yasuhiro¹²^ORCID,Namikawa Kenjiro³^ORCID,Yoshino Koji⁴,Kiniwa Yukiko⁵,Ito Takamichi⁶,Kato Hiroshi⁷,Matsushita Shigeto⁸,Hoashi Toshihiko,Nakamura Yasuhiro,Yoshikawa Shusuke,Miyagawa Takuya,Asai Jun,Matsuya Taisuke,Fukushima Satoshi,Kato Jyunji,Takenouchi Tatsuya,Uchi Hiroshi,Masuzawa Mamiko,Yanagi Teruki,Maekawa Takeo

Affiliation:

1. Department of Dermatology, University of Tsukuba , Tsukuba

2. Department of Dermatology, Ehime University, To-on

3. Department of Dermatologic Oncology, National Cancer Center Hospital , Tokyo

4. Dermatologic Oncology/Dermatology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research , Tokyo

5. Department of Dermatology, Shinshu University , Matsumoto

6. Department of Dermatology, Kyushu University , Fukuoka

7. Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences , Nagoya

8. Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center , Kagoshima , Japan

Abstract

In Japanese patients with melanoma, the response rate of nivolumab plus ipilimumab (N/I) was lower than (35.1%) and the rate of adverse events was similar to (60.4%) those reported in previous clinical trials. No survival difference was observed with the use of N/I between clinical types. Patients who achieved a good response had better outcomes. Elevated lactate dehydrogenase level and having three or more metastatic sites were poor prognostic factors.

Funder

National Cancer Center Research and Development Fund

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljad114/50646278/ljad114.pdf

Reference8 articles.

1. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicentre phase II study;Namikawa;Eur J Cancer,2018

2. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma;Fujisawa;Cancer Med,2019

3. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis;D'Angelo;J Clin Oncol,2017

4. Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients;Maeda;Br J Dermatol,2019

5. Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: retrospective single institutional study;Nakamura;J Dermatol,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial;British Journal of Dermatology;2024-06-04

2. Optimal strategy in managing advanced melanoma;The Journal of Dermatology;2023-12-12

3. A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan;Frontiers in Medicine;2023-12-07